CL2022001355A1 - Uso de un anticuerpo inhibidor de masp-2, o un fragmento del mismo, para el tratamiento del síndrome de neumonía idiopática posterior a un trasplante de células madres hematopoyéticas (hsct-ips). - Google Patents

Uso de un anticuerpo inhibidor de masp-2, o un fragmento del mismo, para el tratamiento del síndrome de neumonía idiopática posterior a un trasplante de células madres hematopoyéticas (hsct-ips).

Info

Publication number
CL2022001355A1
CL2022001355A1 CL2022001355A CL2022001355A CL2022001355A1 CL 2022001355 A1 CL2022001355 A1 CL 2022001355A1 CL 2022001355 A CL2022001355 A CL 2022001355A CL 2022001355 A CL2022001355 A CL 2022001355A CL 2022001355 A1 CL2022001355 A1 CL 2022001355A1
Authority
CL
Chile
Prior art keywords
hsct
masp
ips
fragment
treatment
Prior art date
Application number
CL2022001355A
Other languages
English (en)
Inventor
A Demopulos Gregory
A Dudler Thomas
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of CL2022001355A1 publication Critical patent/CL2022001355A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)

Abstract

In one aspect, the invention provides methods of inhibiting the effects of MASP 2 dependent complement activation in a human subject suffering from, or at risk for developing HSCT-IPS and/or suffering from, or at risk for developing HSCT-CLS and/or suffering from, or at risk for developing HSCT-FO and/or suffering from, or at risk for developing HSCT-ES. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP 2 inhibitory agent effective to inhibit MASP 2 dependent complement activation.
CL2022001355A 2019-11-26 2022-05-24 Uso de un anticuerpo inhibidor de masp-2, o un fragmento del mismo, para el tratamiento del síndrome de neumonía idiopática posterior a un trasplante de células madres hematopoyéticas (hsct-ips). CL2022001355A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940720P 2019-11-26 2019-11-26
US201962940735P 2019-11-26 2019-11-26

Publications (1)

Publication Number Publication Date
CL2022001355A1 true CL2022001355A1 (es) 2023-05-19

Family

ID=76130747

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2022001355A CL2022001355A1 (es) 2019-11-26 2022-05-24 Uso de un anticuerpo inhibidor de masp-2, o un fragmento del mismo, para el tratamiento del síndrome de neumonía idiopática posterior a un trasplante de células madres hematopoyéticas (hsct-ips).
CL2024001421A CL2024001421A1 (es) 2019-11-26 2024-05-13 Uso de composición que comprende un anticuerpo anti masp-2 para tratar síndrome de neumonìa idiopàtica.
CL2024001420A CL2024001420A1 (es) 2019-11-26 2024-05-13 Uso de composición que comprende un anticuerpo anti masp-2 para tratar síndrome de fuga capilar.
CL2024001422A CL2024001422A1 (es) 2019-11-26 2024-05-13 Uso de anticuerpo anti masp-2 para tratar sobrecarga de fluidos después de un trasplante.

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2024001421A CL2024001421A1 (es) 2019-11-26 2024-05-13 Uso de composición que comprende un anticuerpo anti masp-2 para tratar síndrome de neumonìa idiopàtica.
CL2024001420A CL2024001420A1 (es) 2019-11-26 2024-05-13 Uso de composición que comprende un anticuerpo anti masp-2 para tratar síndrome de fuga capilar.
CL2024001422A CL2024001422A1 (es) 2019-11-26 2024-05-13 Uso de anticuerpo anti masp-2 para tratar sobrecarga de fluidos después de un trasplante.

Country Status (13)

Country Link
US (2) US20220064330A1 (es)
EP (1) EP4065165A4 (es)
JP (2) JP2023503611A (es)
KR (1) KR20220104201A (es)
CN (1) CN115335077A (es)
AU (1) AU2020391175A1 (es)
BR (1) BR112022010078A2 (es)
CA (1) CA3159152A1 (es)
CL (4) CL2022001355A1 (es)
IL (1) IL293363A (es)
JO (1) JOP20220113A1 (es)
MX (1) MX2022006334A (es)
WO (1) WO2021108447A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023108028A2 (en) 2021-12-10 2023-06-15 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2704743B1 (en) * 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
CN108472347B (zh) * 2015-11-09 2023-09-05 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
US10736960B2 (en) * 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
RU2018145364A (ru) * 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
EP3526249A4 (en) * 2016-10-17 2020-07-01 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INJURY ASSOCIATED WITH A GRAFT
CA3055781A1 (en) * 2017-03-14 2018-09-20 Bioverativ Usa Inc. Methods for treating complement-mediated diseases and disorders
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
EP3717004A4 (en) * 2017-12-01 2021-12-01 Children's Hospital Medical Center COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
US20240218080A1 (en) 2024-07-04
US20220064330A1 (en) 2022-03-03
CL2024001421A1 (es) 2024-08-23
EP4065165A4 (en) 2024-10-16
KR20220104201A (ko) 2022-07-26
MX2022006334A (es) 2022-06-22
IL293363A (en) 2022-07-01
CL2024001420A1 (es) 2024-08-23
AU2020391175A1 (en) 2022-07-07
CA3159152A1 (en) 2021-06-03
JOP20220113A1 (ar) 2023-01-30
CN115335077A (zh) 2022-11-11
WO2021108447A1 (en) 2021-06-03
JP2023503611A (ja) 2023-01-31
BR112022010078A2 (pt) 2022-12-13
EP4065165A1 (en) 2022-10-05
CL2024001422A1 (es) 2024-08-23
JP2026062897A (ja) 2026-04-10

Similar Documents

Publication Publication Date Title
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
MX2022012380A (es) Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
EA202190377A9 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
AR086582A1 (es) Anticuerpos anti-kir para el tratamiento de trastornos inflamatorios y autoinmunes
MX2021013815A (es) Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer.
EA202091965A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 ИЛИ ДВОЙНОГО ИНГИБИТОРА Bcl-2/Bcl-xL И ИНГИБИТОРА BTK И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
EA202190581A1 (ru) Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a
JOP20210050A1 (ar) معدلات تعبير pnpla3
EA202190073A1 (ru) Композиции и способы лечения видов гемоглобинопатии и талассемии
EA202092489A1 (ru) СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ
CL2020003324A1 (es) Composiciones y métodos para inhibir masp-2 para el tratamiento de diversas enfermedades y trastornos trombóticos.
CL2021000483A1 (es) Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
CL2022000214A1 (es) Inhibidores de enzimas
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
UY38352A (es) Inhibidores de integrina alfavbeta6
JOP20210143A1 (ar) تركيبات وطرق لعلاج ومنع التصلب الجانبي الضموري
CL2020000397A1 (es) Formulaciones de anticuerpos inhibitorio para masp-2 de baja viscosidad altamente concentradas, kits, y métodos de tratamiento de sujetos que sufren de síndrome hemolítico atípico.
CL2022001355A1 (es) Uso de un anticuerpo inhibidor de masp-2, o un fragmento del mismo, para el tratamiento del síndrome de neumonía idiopática posterior a un trasplante de células madres hematopoyéticas (hsct-ips).
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX381311B (es) Método para el tratamiento de prurito y/o comezón.
CO2021007006A2 (es) Moduladores de la expresión de irf5
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa